Glycoconjugates and their use as potential vaccines against infection by Shigella flexneri

Patent metadata

Field	Value
Publication number	US-10376593-B2
Application number	US-201314438750-A
Country	US
Kind code	B2
Filing date	Oct 29, 2013
Priority date	Oct 29, 2012
Publication date	Aug 13, 2019
Grant date	Aug 13, 2019

Abstract

The present invention relates to a conjugate comprising an oligo- or polysaccharide selected from the group consisting of: (X) x -{BCDA} n -(Y) y (X) x -{CDAB} n -(Y) y (X) x -{DABC} n -(Y) y (X) x -{ABCD}n-(Y) y wherein A, B, C, D, X and Y, x, y and n are as defined in claim 1 , said oligo- or polysaccharide being bound to a carrier.

First claim

The invention claimed is:

1. A vaccine composition comprising a physiologically acceptable vehicle and a conjugate comprising an oligo- or polysaccharide selected from the group consisting of:
(X) x -{BCDA} n -(Y) y
(X) x -{CDAB} n -(Y) y
(X) x -{DABC} n -(Y) y
(X) x -{ABCD} n -(Y) y
wherein:
n is an integer comprised between 2 and 10,
A is a beta-d-Galacturonic acid (1,3) residue,
B is a N-acetyl-beta-d-Galactosamine (1,2) residue,
C is independently, at each occurrence, an alpha-I-Rhamnose (1,2) residue, wherein at most one of its 3c or 4c positions is OAc (i.e O—C(═O)CH 3 ), provided that there is at least one occurrence of C wherein the 3c position is not OAc, and provided that when C is a non reducing end residue, its 2c position may be acetylated or not,
D is an alpha-I-Rhamnose (1,4) residue,
x and y are independently selected among 0 and 1,
X and Y are independently selected among A, B, C, D, AB, BC, CD, DA, ABC, BCD, CDA, DAB,
provided that the ratio of 3C-OAc/4C-OAc is greater than 1,
said oligo- or polysaccharide being bound to a carrier.

2. The vaccine composition according to claim 1 , wherein the oligo- or polysaccharide is liable to be bound by an anti-SF6 and/or anti-SF6a antibody.

3. The vaccine composition according to claim 1 , wherein said oligo- or polysaccharide is selected from the group consisting of:
{BCDP} n,
{CDAB} n,
{DABC} n, and
{ABCD} n
wherein A, B, C, and D are as defined in claim 1 and n is an integer comprised between 2 and 10.

4. The vaccine composition according to claim 1 , wherein n is comprised between 2 and 6.

5. The vaccine composition according to claim 1 , wherein the carrier is selected among a protein or a peptide comprising at least one T-helper epitope, or a derivative thereof.

6. The vaccine composition according to claim 5 , wherein the carrier is a Shigella protein able to induce a protective immune response against several Shigella serotypes.

7. The vaccine composition according to claim 1 , wherein the carrier is tetanus toxoid or a fragment thereof.

8. The vaccine composition according to claim 1 , wherein the carrier is a liposome.

9. The vaccine composition according to claim 1 , wherein the oligo- or polysaccharide is bound to the carrier via a spacer which does not contain any carbohydrate residue.

10. The vaccine composition according to claim 1 , wherein the oligo- or polysaccharide to carrier ratio is comprised between 1:1 and 30:1.

11. The vaccine composition according to claim 1 , wherein the oligo- or polysaccharide is {CDAB} n , wherein A, B, C, and D are as defined in claim 1 and n is an integer comprised between 2 and 10.

12. The vaccine composition of claim 1 , further comprising an immunogen which affords protection against another pathogen, such as for example, S. flexneri serotype 1 b, 2a and 3a, members of other Shigella species such as S. sonnei and S. dysenteriae type 1, or pathogens responsible for diarrhoeal disease in humans.

13. The vaccine composition according to claim 1 , which is formulated for parenteral, oral, intranasal, intradermal, subcutaneous or transcutaneous administration.

14. A vaccine composition comprising a physiologically acceptable vehicle and a conjugate comprising an oligo- or polysaccharide (Ia) selected from the group consisting of:
(X) x -{BCDA} n -(Y) y -OQ
(X) x -{CDAB} n -(Y) y -OQ
(X) x -{DABC} n -(Y) y -OQ
(X) x -{ABCD} n -(Y) y -OQ
Wherein:
A, B, C, D, X, Y, x, y and n are as defined in claim 1 , provided that the ratio of 3C-OAc/4C-OAc is greater than 1,
O is the C 1 oxygen atom of the reducing end residue of the oligo- or polysaccharide,
Q is H, or a group LZ,
L is a divalent C 1 -C 12 alkyl or alkenyl chain optionally interrupted by one or more heteroatoms, notably selected from an oxygen atom, a sulphur atom or a nitrogen atom, said nitogen and sulphur atoms being optionally oxidized, and the nitrogen atom being optionally involved in an acetamide bond, and
Z is a terminal reactive function, optionally protected, able to form a covalent bond with a carrier and/or a solid support.

15. The vaccine composition of claim 14 , wherein Z is Hal, biotin, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, azido, alkoxy, epoxyde, acetal, C(═O)H, SR 1 , NH 2 or NHC(═O)CH 2 Hal,
R 1 being H, C(═O)CH 3 or SR 2 , and
R 2 being a C 1 -C 6 alkyl, a C 6 -C 10 aryl, or a 5 to 7 membered heteroaryl, such as pyridyl, or any group allowing to convert SSR 2 into SH.

16. The vaccine composition according to claim 14 , which is immobilized on a solid support.

17. A vaccine composition comprising a physiologically acceptable vehicle and a conjugate comprising an oligo or polysaccharide (Ib) selected from the group consisting of:
(X) x -{BCDA} n -(Y) y -W
(X) x -{CDAB} n -(Y) y -W
(X) x -{DABC} n -(Y) y -W
(X) x -{ABCD} n -(Y) y -W
Wherein:
A is a beta-d-Galacturonic (1,3) acid residue,
B is a N-protected-beta-d-Galactosamine (1,2) residue, wherein said N-protecting group is an acetyl group, or a precursor thereof such as a N-trichloroacetyl group,
C is an alpha-I-Rhamnose (1,2) residue, wherein at most one of 3c or 4c is OAc,
D is an alpha-I-Rhamnose (1,4) residue,
x and y are independently selected among 0 and 1,
n is an integer comprised between 2 and 10,
X and Y are independently selected among A, B, C, D, AB, BC, CD, DA, ABC, BCD, CDA, DAB,
provided that the ratio of 3C-OAc/4C-OAc is greater than 1,
wherein each OH and/or CO 2 H group of said residues are optionally protected by a protecting group,
W is OR i , SR ii or Hal, wherein said O, S and Hal are the C 1 heteroatom of the reducing end residue of the oligo- or polysaccharide chain, S being optionally oxidized,
R i is H, a hydroxyl protecting group, an anomeric hydroxyl activating group, or a LZ group, L and Z being as defined above for formula (Ia),
R ii is C 1 -C 12 alkyl, C 6 -C 10 aryl, an imidate leading preferably to S-thiazolinyl (STaz) or S-benzoxazolyl (SBox).

18. An oligosaccharide which is selected from the group consisting of:
Benzyl (4-O-benzyl-3-O-para-methoxybenzyl-α-I-rhamnopyranosyl)-(1→2)-(3,4-di-O-benzyl-α-I-rhamnopyranosyl)-(1→4)-(allyl 2,3-di-O-benzyl-β-d-galactopyranosid)uronate,
Allyl (4-O-benzyl-3-O-para-methoxybenzyl-α-I-rhamnopyranosyl)-(1→2)-(3,4-di-O-benzyl-α-I-rhamnopyranosyl)-(1→4)-(benzyl 2,3-di-O-benzyl-β-d-galactopyranosyluronate)-(1→3)-4,6-di-O-benzyl-2-deoxy-2-trichloroacetamido-β-d-galactopyranoside,
3,4,6-Tri-O-benzyl-2-deoxy-2-trichloroacetamido-α/β-d-galactopyranosyl N-phenyltrifluoroacetimidate,
Allyl (2,3-di-O-benzyl-β-d-galactopyranosyl)-(1→3)-4,6-di-O-benzyl-2-deoxy-2-trichloroacetamido-β-d-galactopyranoside,
Allyl (benzyl 2,3-di-O-benzyl-β-d-galactopyranosyluronate)-(1→3)-4,6-di-O-benzyl-2-deoxy-2-trichloroacetamido-β-d-galactopyranoside,
Allyl (benzyl 2,3-di-O-benzyl-4-O-levulinoyl-β-d-galactopyranosyluronate)-(1→3)-4,6-di-O-benzyl-2-deoxy-2-trichloroacetamido-β-d-galactopyranoside,
(Benzyl 2,3-di-O-benzyl-4-O-levulinoyl-β-d-galactopyranosyluronate)-(1→3)-4,6-di-O-benzyl-2-deoxy-2-trichloroacetamido-α/β-d-galactopyranose,
Benzyl 2,3-di-O-benzyl-4-O-levulinoyl-β-d-galactopyranosyluronate-(1→3)-4,6-di-O-benzyl-2-deoxy-2-trichloroacetamido-α/β-d-galactopyranosyl N-phenyltrifluoroacetimidate,
Benzyl 2,3-di-O-benzyl-4-O-levulinoyl-β-d-galactopyranosyluronate-(1→3)-4,6-di-O-benzyl-2-deoxy-2-trichloroacetamido-α/β-d-galactopyranosyl trichloroacetimidate,

(3,4-Di-O-benzyl-2-O-levulinoyl-α-I-rhamnopyranosyl)-(1→4)-

Assignees

• Pasteur Institut
• Centre Nat Rech Scient
• Inst Nat Sante Rech Med
• Univ Paris Descartes

Inventors

• Mulard Laurence
• Chassagne Pierre
• Sansonetti Philippe
• Phalipon Armelle
• Traincard Francois
• Nato Farida

Classifications

• A61K47/549

  Sugars, nucleosides, nucleotides or nucleic acids · CPC title

• C07K17/10

  the carrier being a carbohydrate · CPC title

• A61K9/1271

  Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911}) · CPC title

• A61K38/164

  from bacteria · CPC title

• Y02A50/475

  Cross-Sectional Technologies · mapped topic